Abstract
The concept of cardiac remodeling implies a complex mixture of myocardial ischemia, and increased wall stress that results in molecular, cellular and interstitial changes in the heart. Clinically, cardiac remodeling is manifested as a change in size, shape and function of the heart. Morphologically the key feature of remodeling is myocyte hypertrophy, myocyte loss from necrosis or apoptosis, as well as interstitial cell growth especially fibroblast proliferation leading to myocardial fibrosis. Cardiac remodeling is influenced by hemodynamic load, neurohumoral activation, and other factors that can further affect the remodeling process. Despite advances in the management of heart failure, morbidity and mortality still present major health care issues in these patients. Statins (HMG Coenzyme A reductase inhibitors) play a key role in the management of ischemic heart disease. Recent studies indicate that statins may modulate cardiac remodeling by affecting signals that cause fibroblast growth, and myocyte hypertrophy and loss. In this paper we review the mechanisms of cardiac remodeling and the mechanisms of potential beneficial effects of statins on cardiac remodeling.
Keywords: statins, cardiac remodeling, heart failure, cardiomyopathy, fibrosis, hypertrophy
Current Vascular Pharmacology
Title: Modulation of Cardiovascular Remodeling with Statins: Fact or Fiction?
Volume: 3 Issue: 1
Author(s): Rajasekhar Reddy, Georges Chahoud and J. L. Mehta
Affiliation:
Keywords: statins, cardiac remodeling, heart failure, cardiomyopathy, fibrosis, hypertrophy
Abstract: The concept of cardiac remodeling implies a complex mixture of myocardial ischemia, and increased wall stress that results in molecular, cellular and interstitial changes in the heart. Clinically, cardiac remodeling is manifested as a change in size, shape and function of the heart. Morphologically the key feature of remodeling is myocyte hypertrophy, myocyte loss from necrosis or apoptosis, as well as interstitial cell growth especially fibroblast proliferation leading to myocardial fibrosis. Cardiac remodeling is influenced by hemodynamic load, neurohumoral activation, and other factors that can further affect the remodeling process. Despite advances in the management of heart failure, morbidity and mortality still present major health care issues in these patients. Statins (HMG Coenzyme A reductase inhibitors) play a key role in the management of ischemic heart disease. Recent studies indicate that statins may modulate cardiac remodeling by affecting signals that cause fibroblast growth, and myocyte hypertrophy and loss. In this paper we review the mechanisms of cardiac remodeling and the mechanisms of potential beneficial effects of statins on cardiac remodeling.
Export Options
About this article
Cite this article as:
Reddy Rajasekhar, Chahoud Georges and Mehta L. J., Modulation of Cardiovascular Remodeling with Statins: Fact or Fiction?, Current Vascular Pharmacology 2005; 3 (1) . https://dx.doi.org/10.2174/1570161052773915
DOI https://dx.doi.org/10.2174/1570161052773915 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Preface
Current Drug Targets - Infectious Disorders Role of Intra-Luminal Pressure in Regulating PBF in the Fetus and After Birth
Current Pediatric Reviews Pneumonia in the Elderly
Current Respiratory Medicine Reviews Atherosclerotic Plaque Biomarkers: Beyond the Horizon of the Vulnerable Plaque
Current Cardiology Reviews Hemodynamic Monitoring in the Acute Management of Pediatric Heart Failure
Current Cardiology Reviews Diminished Renal Function and the Incidence of Heart Failure
Current Cardiology Reviews Human Embryonic Stem Cell-Derived Cardiomyocytes for Heart Therapies
Cardiovascular & Hematological Disorders-Drug Targets Hyperuricaemia and Non-Alcoholic Fatty Liver Disease (NAFLD): A Relationship with Implications for Vascular Risk?
Current Vascular Pharmacology Carotid Artery Atherosclerosis: What is the Evidence for Drug Action?
Current Pharmaceutical Design Managing Erectile Dysfunction in Heart Failure
Endocrine, Metabolic & Immune Disorders - Drug Targets Hypertension, Prehypertension and Blood Pressure Related Diseases
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Drug Eluting Coronary Artery Stents
Current Drug Delivery Transdermal Delivery of Captopril and Metoprolol Tartrate with Microneedles
Drug Delivery Letters Manipulation and Engineering of Metabolic and Biosynthetic Pathway of Plant Polyphenols
Current Pharmaceutical Design Discovery of Chromen-7-yl Furan-2-Carboxylate as a Potent and Selective Factor XIa Inhibitor
Cardiovascular & Hematological Agents in Medicinal Chemistry Biomarkers Linking PCB Exposure and Obesity
Current Pharmaceutical Biotechnology Medicinal Plants with Multiple Effects on Cardiovascular Diseases: A Systematic Review
Current Pharmaceutical Design Vascular Stiffness: Measurements, Mechanisms and Implications
Current Vascular Pharmacology Effects of Diets on Adipose Tissue
Current Medicinal Chemistry Patent Annotations
Recent Patents on Cardiovascular Drug Discovery